Johnson & Johnson announced that it has entered into a definitive agreement to acquire Atraverse Medical, a privately held medical device company focused on next-generation left-heart access and radiofrequency technology. The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions. Financial terms were not disclosed.
Atraverse Medical has developed the HOTWIRE Transseptal Access System, an FDA-cleared radiofrequency guidewire and generator platform designed to improve the safety and precision of accessing the left atrium during cardiac procedures. The system has already been used in nearly 3,000 clinical procedures and incorporates features such as impedance-sensing automatic energy shutoff, compatibility with multiple sheaths, and enhanced tip visibility under intracardiac echocardiography.
Access to the left atrium is a critical step in procedures such as atrial fibrillation ablation, where precision and control are essential for effective treatment. Atraverse Medical’s technology is designed to streamline this process, supporting electrophysiologists with tools that improve procedural efficiency and outcomes.
The acquisition is expected to strengthen Johnson & Johnson’s portfolio of cardiac ablation solutions, expanding its capabilities in treating atrial fibrillation and other cardiac arrhythmias. By integrating Atraverse Medical’s technology, the company aims to enhance its offering of minimally invasive solutions for cardiovascular care.
Johnson & Johnson continues to invest in advanced medical technologies across its cardiovascular portfolio, focusing on innovation that improves clinical outcomes and supports healthcare providers in complex procedures.
